Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
6/2/2026, 12:00:00 AM
European Commission approved AQUIPTA (atogepant) for acute migraine treatment on 2026-06-02. Low importance as label expansions typically result in moderate price movement.
Korean Translation
2026년 6월 2일, 유럽연합 집행위원회가 아큅타(아토게판트)의 편두통 급성 치료 적응증 확대를 승인함. 적응증 확대에 따른 통상적인 시장 반응을 고려하여 중요도를 낮게 평가함.
Related Recent Events
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is scheduled to report its Q2 2026 financial results; earnings releases typically result in price moves of 5% or more, scheduled.
8/14/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
Next earnings release for Q2 2026 on 2026-08-03 is scheduled. Low importance is estimated for the scheduling announcement itself.
8/3/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q2 2026 earnings release is scheduled.
7/28/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Intuitive Surgical's Q2 2026 earnings release, a major stock catalyst, is scheduled.
7/21/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Other
2026 Annual Meeting of Stockholders scheduled for June 17, 2026. Market reaction not yet occurred; low importance assigned due to likely <5% price impact from annual meeting scheduled.
6/17/2026, 12:00:00 AM